Bond.az White LogoBond.az Black Logo

Compass Point Lowers DeFi Tech Target

Compass Point cuts DeFi Technologies price target to $1.45, maintains Buy rating amid bear market.

Charlotte Hernandez
ByCharlotte Hernandez- Senior Editor
|
0

Compass Point lowered its price target on DeFi Technologies (NASDAQ:DEFT) to $1.45 from $1.50, maintaining a Buy rating.

The stock trades at $87.1, down 27% over the past year and 14% in the last six months.

Q1 fee revenue was $6.3 million, reflecting deep bear market conditions. Outflows reached $1.7 million in Q1 2026.

Assets under management stand at about $550 million. Quarter-to-date inflows have reaccelerated to $15 million.

The company has a $100 million enterprise value. The price target applies a 12x multiple to the prior $30 million EBITDA run rate.

About 60-70% of AUM is in Altcoin ETPs. Compass Point says DeFi Technologies offers the most leverage to higher crypto prices.

More News
Today / 12:32
|
795

Morgan Stanley Reiterates Home Depot Rating on Execution

Morgan Stanley reiterates Overweight rating on Home Depot with $420 target, citing solid execution in a growthless housing market.

0
Today / 12:30
|
656

Benchmark Reiterates Baidu Stock Rating on AI Revenue Milestone

Benchmark reaffirms Buy rating on Baidu after AI revenue milestone. AI Cloud margins improve, new products launched.

0
Today / 12:04
|
952

Raymond James Backs Nutrien Stock on Potash

Raymond James backs Nutrien stock with Outperform rating and $90 target after Indian potash deal. 26% upside, strong financials.

0
Today / 11:35
|
858

Mizuho Raises STM Price Target on AI Growth

Mizuho raises STMicroelectronics price target to $68, citing AI growth and new technologies.

0
Today / 11:03
|
967

Oppenheimer Reiterates Outperform on UroGen Pharma

Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.

0
Today / 11:02
|
510

Guggenheim Upgrades StubHub Stock on Reset

Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.

0
Today / 10:31
|
290

Wolfe Research Initiates CytomX Stock with Outperform

Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.

0
Today / 10:30
|
842

Wolfe Research initiates Mirum with outperform

Wolfe Research starts Mirum Pharmaceuticals with outperform rating and $145 price target, citing strong pipeline potential.

0
Today / 10:14
|
236

Wolfe Research Initiates Oklo with Peerperform

Wolfe Research initiated Oklo Inc. with a Peerperform rating. Learn about the company's targets, finances, and stock performance.

0
Today / 10:13
|
631

Aletheia Capital Reaffirms Circle Stock Rating

Aletheia Capital reaffirms Buy rating on Circle Internet Group amid U.S. stablecoin regulatory advantages. Stock at $111.39.

0
Today / 09:31
|
784

Jefferies Initiates X-Energy Stock with Hold Rating

Jefferies initiates X-Energy stock coverage with a Hold rating and $28 target. Learn about risks and recent performance.

0
Today / 09:11
|
441

UBS Upgrades Jazz Pharma on Ziihera Potential

UBS upgrades Jazz Pharmaceuticals to Buy with a $307 target on Ziihera potential. Bond.az provides detailed analysis and stock insights.

0
...
Compass Point Lowers DeFi Tech Target | Bond.az